BCL2 and neoplasm: Among the 11 genes selected we could successfully amplify 9 of them, of which 8 differentially spliced between basal-like tumours and normal samples (AURKA, AURKB, BCL2-a, NEK2, RRM2, TGFBR1, UBE2C, ZBTB16) and 2 differentially spliced in basal-like tumours, between patients with respectively better and worse outcome (CCR7, TGFBR1).